Meeting
2023 ASCO Gastrointestinal Cancers Symposium
A phase Ia/Ib, open-label, dose escalation study of the TRAILR2 agonist BI 905711 in combination with chemotherapy (CT) in patients (pts) with advanced GI cancers.
Authors
Scott Kopetz
The University of Texas MD Anderson Cancer Center, Houston, TX;
Scott Kopetz , Eric Van Cutsem , Yasutoshi Kuboki , Benny Johnson , Tetsuya Katakabe , Min He , Shorena Archuadze , Lin Shen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Other
Clinical Trial Registration Number
NCT05087992
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr TPS820)
DOI
10.1200/JCO.2023.41.4_suppl.TPS820
Abstract #
TPS820
Poster Bd #
P10
Abstract Disclosures
Similar Posters
Poster
2012 Gastrointestinal Cancers Symposium
Phase II study alternating mFOLFOX 6 and FOLFIRI (FIREFOX) plus bevacizumab (bev) regimen in first-line treatment of advanced colorectal cancer in Japanese patients (KSCC 0801).
First Author: Yutaka Ogata
Poster
2022 ASCO Annual Meeting
Phase II study of nivolumab in combination with FOLFOXIRI/bevacizumab as first-line treatment in patients with advanced colorectal cancer RAS/BRAF mutated (mut): NIVACOR trial (GOIRC-03-2018).
First Author: Angela Damato
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Anlotinib combined with mXELIRI as second-line treatment in advanced colorectal cancer pretreated with bevacizumab plus standard chemotherapy: A single-arm, phase IB/II study.
First Author: Xin Qu
Poster
2022 ASCO Gastrointestinal Cancers Symposium
NeoOPTIMIZE: An open-label, phase II trial and biomarker discovery platform to assess the efficacy of adaptive switching of modified FOLFIRINOX (mFFX) or gemcitabine/nab-paclitaxel (GA) as a neoadjuvant strategy for patients with resectable/borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).
First Author: Charles D. Lopez